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Abstract Prepulse inhibition (PPI) may useful for
exploring the proposed shared neurobiology between idio-
pathic autism and autism caused by FXS. We compared PPI
in four groups: typically developing controls (n = 18), FXS
and autism (FXS?A; n = 15), FXS without autism spec-
trum disorder (FXS-A; n = 17), and idiopathic autism (IA;
n = 15). Relative to controls, the FXS?A (p \ 0.002) and
FXS-A (p \ 0.003) groups had impaired PPI. The FXS?A
(p \ 0.01) and FXS-A (p \ 0.03) groups had lower PPI
than the IA group. Prolonged startle latency was seen in the
IA group. The differing PPI profiles seen in the FXS?A and
IA indicates these groups may not share a common neuro-
biological abnormality of sensorimotor gating.
Keywords PPI  FMR1 gene  Sensorimotor gating 
mGluR5  Prepulse inhibition  Startle
Fragile X syndrome (FXS) is the most common inherited
form of intellectual disability and the leading known cause
of autism. FXS results from a trinucleotide repeat expan-
sion, leading to a decrease of the FMR1 protein (FMRP).
FMRP moderates RNA transcription and directly influ-
ences many other proteins, and diminished FMRP results in
aberrant brain development. Consequently, individuals
with FXS display a phenotype characterized by cognitive
impairment, social and communication deficits, stereotypic
behavior, gaze aversion, attention deficits, hyperactivity,
aggression, hyperarousal, and sensory abnormalities.
Individuals with idiopathic autism also demonstrate
many of these behavioral, social, and sensory abnormali-
ties. The rate of FXS in those with autism varies from 2 to
8% when utilizing DNA testing (Estecio et al. 2002;
Wassink et al. 2001). The reported prevalence of autism
within the FXS population has ranged from 15 to 33%
(Bailey et al. 2001; Harris et al. 2008; Reiss and Freund
1992; Rogers et al. 2001), and 30% meet criteria for a
diagnosis of Pervasive Developmental Disorder—Not
Otherwise Specified (PDD-NOS). Additionally, 50–90% of
individuals with FXS have significant autistic-like behav-
iors (such as gaze avoidance, stereotypies, etc.) even
without meeting formal diagnostic criteria for PDD-NOS
or autism. The large overlap in phenotypic profiles between
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the two groups has led to a hypothesis that FXS and autism
may share a common neurobiology.
Pre-pulse inhibition (PPI) is a well-documented indicator
of sensorimotor gating, a process important for filtering
extraneous sensory information from the external environ-
ment. PPI is an objective measure of the attenuation of a
startle response to an intense auditory stimulus, when that
stimulus is preceded by an innocuous tone. PPI is mediated
through a neurological pathway involving the pontine
brainstem, which receives modulatory input from the pre-
frontal cortex, hippocampus, and amygdala as these struc-
tures converge on the nucleus accumbens (Schmajuk and
Larrauri 2005). PPI is regulated by many neurotransmitter
systems, including the glutamatergic receptor pathways such
as the mGluR (Zou et al. 2007), GABA (Arai et al. 2008;
Bortolato et al. 2007; Fendt 1999; Kodsi and Swerdlow
1995), and NMDAR receptor systems (Wolf et al. 2007).
A PPI deficit in males with FXS was first demonstrated
by Frankland and colleagues (2004), and subsequently
replicated by our laboratory in a larger sample of males and
females (Hessl et al. 2008). PPI impairment in high func-
tioning autism or Asperger’s Disorder has been reported
and associated with inhibitory control problems (McAlo-
nan et al. 2002) or restricted and repetitive behaviors (Perry
et al. 2007). However, an earlier study was unable to
demonstrate a significant PPI deficit in high and low-
functioning individuals with autism (Ornitz et al. 1993).
The aim of the current study was to directly compare
PPI in individuals with FXS (with and without autism) with
individuals with idiopathic autism as well as typically-
developing controls, to uncover potential commonalities in
the neurobiological processes underlying the shared phe-
notypic characteristics.
Methods
Seventy-one individuals were enrolled and were divided
into four groups based on their clinical diagnoses: fragile X
with autism (FX?A), fragile X without autism (FX-A),
idiopathic autism (IA), or typically developing control (C).
Participants were consecutive clinic referrals or enrolled
through the M.I.N.D. Institute recruitment sources. Study
enrollment and final group demographics can be seen in
Fig. 1 and Table 1, respectively. Individuals were age-
matched across all groups, and individuals in the FXS?A
and IA groups were also IQ matched.
Thirteen of the individuals included in the final analyses
were previously reported in Hessl et al. 2008 (8 FX-A, 3
FX?A, 2 C). Psychoactive medication use by subjects in
each group is shown in Table 2.
Exclusion criteria included known hearing loss, facial
motor tics, and central nervous system involvement other
than autism or FXS (e.g., cerebral palsy, fetal alcohol
syndrome, or serious head injury). In addition, control
subjects were excluded if they had any history of psychi-
atric diagnoses or learning disabilities.
Fragile X full mutation status was confirmed through
FMR1 DNA testing using PCR and Southern Blot as
described in Tassone et al. (2008), and all participants in
the IA group were confirmed negative. Autistic Disorder
was determined using the Autism Diagnostic Observation
Schedule (Lord et al. 2002) and DSM-IV criteria. When
possible, the Autism Diagnostic Interview (Lord et al.
1994) and Social Communication Questionnaire (Rutter
et al. 2003) were utilized to help confirm diagnosis. Only
those individuals meeting criteria for full Autistic Disorder
or no autism were included in the final study groups.
Fig. 1 Summary of initial study
enrollment and breakdown to
number of subjects included in
the final analyses
Table 1 Summary of participant demographics in each study group,
including age and gender breakdown
Group N Males
(N)
Females
(N)
Age (Mean,
range)
IQ (Mean,
SD)
FXS-A 17 4 13 15.49 (11–23) 68.65, 15.2
FXS?A 15 13 2 17.04 (10–24) 55.07, 3.9
IA 15 13 2 16.83 (14–23) 56.47, 6.6
C 18 11 7 16.61 (11–24) 119.17, 11.3
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The PPI data collection and videocoding followed the
protocol previously described in detail (Hessl et al. 2008).
Trial types consisted of 105 db white noise startle stimuli
(SS) or prepulse trials consisting of 25 ms, 75db, 1 kHz
tones occurring 60, 120, or 240 ms prior to the SS. The trial
order was random, and inter-trial intervals ranged from 25
to 45 s. EMG startle data was visually scrutinized, and the
validity of each trial was confirmed using standardized
videocoding of behavior prior to data analysis as previ-
ously described.
A log transformation of the data was employed to nor-
malize the distributions for subsequent analyses. Percent
PPI for each prepulse trial type was calculated using fol-
lowing equation: 100 X [(response amplitude in the startle
stimulus alone trials—response amplitude in the prepulse
trials)/response amplitude in the startle stimulus alone
trials].
Results
Mean startle amplitude to the SS (no prepulse) was com-
pared across groups (Table 3). Analysis of variance
(ANOVA) showed no significant between group differ-
ences, F (3, 53) = 0.29, p = 0.83.
Startle latency to the SS showed positive skew with
notable outliers. Transformation of the data was not suc-
cessful, and therefore group differences were analyzed
using non-parametric tests. A Kruskal–Wallis test revealed
a main effect of group, p = 0.001. Pairwise group com-
parisons showed that the IA group had a longer latency
than each of the other three groups (all p \ 0.01; Fig. 2).
For PPI, a repeated measures ANOVA, with prepulse
interval type as the repeating dependent variable and group
as the independent variable revealed main effects of trial
type [F(2) = 9.22, p \ 0.001] and group [F(3, 59) = 5.63,
p = 0.002]. Post-hoc pairwise comparisons (Fisher’s LSD)
showed that participants with FXS?A (p = 0.002) and
FXS-A (p = 0.003) had lower PPI than C. In addition, the
FXS-A (p = 0.03) and FXS?A (p = 0.01) groups had
lower PPI than the IA group. All other group comparisons
and group by trial type interactions were non-significant,
including the comparison between the IA and C groups
(Fig. 3 and Table 3). There was a consistent trend across
all interval trial types with PPI increasing from FXS-A to
FXS?A to IA to controls.
As noted in the participant descriptions, gender ratios
across groups were not equivalent, especially within the
FXS?A (higher proportion of males) and FXS-A (higher
proportion of females). Because different gender ratios
may confound observed differences between groups, we
analyzed PPI group differences for males only for IA
(n = 9), FXS?A (n = 11), and C (n = 10) groups, using
non-parametric tests. A Kruskal–Wallis test revealed a
main effect of group for the 60, 120, and 240 ms intervals
(p = 0.03, p = 0.007, and p = 0.006, respectively). Pair-
wise group comparisons with Mann–Whitney tests dem-
onstrated significant differences between C and FXS?A
(p \ 0.01 for all intervals) and between IA and FXS?A
groups for the 120 and 240 ms intervals (p = 0.02 and
p = 0.02, respectively; Fig. 4). All three groups were
matched on age (IA = 17.1, FXS?A = 17.5, and
C = 16.61 years). The IA and FXS?A groups were addi-
tionally matched on IQ (IA = 56.3 and FXS?A = 54.6).
Table 2 Summary of the number of participants in each clinical group taking different types of medication at the time of testing
Group (n) No medication SSRI/SNRI Anti- psychotics Stimulants Anti- convulsants Anti-anxiety Sedatives Other
antidepressants
FXS-A (17) 6 8 4 3 0 1 0 2
FXS?A (15) 5 7 3 4 0 2 0 1
IA (14) 4 5 4 1 2 0 0 0
C (18) 18 0 0 0 0 0 0 0
*
*
*
Fig. 2 Latency of peak startle response by group (including males
and females). Nonparametric tests revealed a longer latency in the
idiopathic autism group relative to the typical control (p \ 0.001),
FXS with autism (p \ 0.002) and FXS without autism (p \ 0.004)
groups. All groups were age-matched, and the FXS?A and IA groups
were IQ-matched
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Discussion
We directly compared sensorimotor gating in individuals
with idiopathic autism and a well-matched group of indi-
viduals with autism associated with fragile X syndrome to
investigate a possible shared neurobiological endopheno-
type. The two FXS groups in the study (with and without
autism) had significantly lower PPI when compared to age-
matched controls, consistent with previous studies docu-
menting deficits in sensorimotor gating and inhibition
mechanisms related to the FMR1 mutation. The direct
comparison of the two groups with autism matched on both
age and IQ demonstrated that PPI is more impaired in
individuals with autism associated with FXS than in those
with idiopathic autism. Thus, the data do not support a
shared trait of sensorimotor gating abnormality in these
two populations, even though they manifest similar autistic
symptoms such as stereotypic behaviors, social reciprocity
deficits, and communication impairment. This interpreta-
tion is consistent with a recent examination of brain mor-
phology in children with autism and children with FXS
who demonstrated similar behavioral and cognitive profiles
but differed markedly in the volumes of specific brain
regions (Cody-Hazlett et al. 2009). More robust sample
sizes are needed to further investigate whether subtypes
exist in IA populations with regard to PPI performance.
Gender was identified as a potential confounder in this
investigation. Nonetheless, we were able to demonstrate
significant differences between the two groups with autism
in males only. Study groups with a more equal gender
distribution (i.e. greater numbers of males with FXS-A or
females with FXS?A or IA) would provide more reliable
contrasts in PPI across these groups of interest.
Many of our study participants were taking psychoactive
medications at the time of data collection. Although the
sample size was too small to examine effects of specific
types of medications, we found no significant differences in
PPI between those taking and not taking medications at the
time of testing (data not shown). A more thorough exam-
ination of the potential impact of psychoactive medications
on PPI performance in FXS can be found in Hessl et al.
(2008).
Fig. 3 Prepulse inhibition (PPI)
in each group (including males
and females), by prepulse
interval trial type.
C = Typically developing
controls, IA = Idiopathic
Autism, FXS?A = fragile X
syndrome with autism, FXS-
A = fragile X syndrome
without autism. PPI was
significantly lower in FXS?A
(p = 0.002) and FXS-A
(p = .003) compared with
controls. PPI was also
significantly lower in FXS?A
(p = .01) and FXS-A
(p = .03) compared to IA
Table 3 Descriptive statistics of the amplitude of startle response to stand-alone startle stimulus (in mV) and prepulse inhibition (PPI; %
inhibition) in individuals with FXS-A, FXS?A, IA and controls; descriptive statistics of PPI are further broken down by prepulse interval
FXS-A (n = 17) FXS?A (n = 15) IA (n = 15) C (n = 18)
Mean SD Mean SD Mean SD Mean SD
105 dB SS (mV) 101.71 54.8 94.64 91.98 90.17 71.61 95.99 75.64
Prepulse interval (%)
60 ms 30.11 26.95 38.55 24.44 50.43 22.30 60.25 17.43
120 ms 33.75 28.76 35.00 21.07 47.94 23.61 58.49 22.30
240 ms 8.21 34.93 29.36 20.80 38.16 28.56 53.63 19.30
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Significant differences in startle latency were found
between the idiopathic autism group and the fragile X
groups, as well as typically developing controls. Ornitz
et al. (1993) found longer latency to auditory stimuli in
autism relative to controls, though this effect did not reach
statistical significance. The longer startle latency in idio-
pathic autism may be associated with disruption of the
basic startle reflex pathway involving primarily brain stem
circuits, such as the auditory brainstem response abnor-
malities in autism previously reported (Fujikawa-Brooks
et al. 2010) .
We were unable to document a significant PPI deficit in
our idiopathic autism group. Although the prior research of
Perry et al. (2007) and McAlonan et al. (2002) showed PPI
deficits associated with autism, these studies included
higher functioning adults with autism or Asperger’s Dis-
order, whereas our sample included much lower function-
ing children and adolescents. The only prior work which
studied PPI in low-functioning individuals with autism was
conducted by Ornitz et al. (1993). That study, which
included a cohort of individuals with both high- and low-
functioning individuals with autism, revealed no significant
PPI deficit. The inconsistency in PPI results may be
explained by autism cohort or protocol differences such as
type and intensity of prepulse and startle stimuli. Again,
larger sample sizes in future studies may be necessary to
reveal true deficits in PPI that may exist in children with
autism, or specific subgroups.
The mGluR theory of FXS postulates that upregulation
of mGluR5-mediated activity seen in the absence of FMRP
may contribute to the clinical features of the disorder. In
animal studies, mGluR5 negative modulators have been
shown to rescue behavioral, cognitive, and prepulse inhi-
bition deficits in fmr1 knockout fruit fly and mouse models
(de Vrij et al. 2008; Dolen et al. 2007; McBride et al. 2005;
Yan et al. 2005). As such, clinical trials employing the use
of similar mGluR5 antagonists have moved to the forefront
of research efforts to produce clinical improvements in
humans with FXS. If mGluR dysregulation plays a role in
sensorimotor gating deficits in FXS, it may also play a
similar role a subset of individuals with IA demonstrating
PPI deficits. Thus, demonstration of the commonalities in
the neurobiological processes underlying PPI deficits
between individuals from phenotypically-related clinical
groups may have implications for future collaboration in
targeted treatment efforts.
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